Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Marc Usart
Observed name:
MARC Usart
Institutions:
Baylor College of Medicine,
University of Basel,
University Hospital of Basel,
Dan L Duncan Comprehensive Cancer Center
Observed institutions:
Boston Children's Hospital,
Harvard University,
Baylor College of Medicine,
University of Basel,
University Hospital of Basel,
Dan L Duncan Comprehensive Cancer Center,
Palacký University Olomouc
show all 7
ORCID:
0009-0002-4575-8029
Observed ORCID:
0009-0002-4575-8029
OpenAlex ID:
A5059110220
Single-cell lineage tracing unveils a role for TCF15 in haematopoiesis
2020
·
Alejo E. Rodriguez-Fraticelli
, Caleb Weinreb
, et al.
·
Nature
·
290
IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK2 -mutant hematopoietic stem cells
2024
·
Shivam Rai
, Yang Zhang
, et al.
·
Blood Advances
·
48
PDF
Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms
2023
·
Jan Stetka
, Marc Usart
, et al.
·
Blood
·
29
PDF
The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN
2024
·
Marc Usart
, Nils Hansen
, et al.
·
Blood Advances
·
27
PDF
Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2 -V617F–positive myeloproliferative neoplasms
2024
·
Marc Usart
, Jan Stetka
, et al.
·
Blood
·
24
PDF
The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs)
2022
·
Shivam Rai
, Jan Stetka
, et al.
·
Blood
·
17
Combination of 5-Azacytidine and Pegifna Is Able to Overcome Resistance in JAK2-V617F Positive MPN with Loss of Dnmt3a
2022
·
Melissa Lock
, Damien Luque Paz
, et al.
·
Blood
·
5
AJ1-11095, a potent and highly selective type-II JAK2 inhibitor, shows enhanced therapeutic efficacy as compared with type-I JAK2 inhibitor ruxolitinib in models of myeloproliferative neoplasms (MPNs)
2025
·
Marc Usart
, Shivam Rai
, et al.
·
Blood
·
3
PDF
Loss of Socs2 improves molecular responses to IFNα in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F
2025
·
Marc Usart
, Quentin Kimmerlin
, et al.
·
Leukemia
·
3
Inhibiting Glutamine Metabolism with CB-839 Reduces Erythrocytosis in MPN Mice
2021
·
MARC Usart
, Shivam Rai
, et al.
·
Blood
·
2
JAK2-V617F-Driven Myeloproliferative Neoplasms (MPN) Are Initiated By a Subset of HSCs Marked By High Expression of the Vwf-GFP Reporter Gene
2024
·
Quentin Kimmerlin
, Marc Usart
, et al.
·
Blood
·
1
PDF
Cellular Barcoding of JAK2-V617F Hematopoietic Stem Cells Reveals No Substantial Preferences in the Contribution of Individual Stem Cell Clones to Erythroid Versus Megakaryocytic Lineages
2023
·
Marc Usart
, Tiago Almeida
, et al.
·
Blood
·
1
Generation of a novel knock-in mouse line expressing oncogenic Kit D814V in the hematopoietic stem cell compartment as a preclinical model for systemic mastocytosis
2026
·
Simona Stivala
, Alina Makeeva
, et al.
·
Leukemia
PDF
A single JAK2 ‐V617F hematopoietic stem cell can initiate myeloproliferative neoplasm when transplanted into non‐conditioned recipient mice
2026
·
Quentin Kimmerlin
, Morgane Hilpert
, et al.
·
HemaSphere
Soluble ST2 as a potential biomarker and therapeutic target in systemic mastocytosis
2026
·
Karin Hartmann
, Etnik Sheremeti
, et al.
·
Journal of Allergy and Clinical Immunology
Exploring the Functional Role of an Alternative mRNA Transcript of the EPO Gene
2022
·
Cédric B. Stoll
, Marc Usart
, et al.
·
Blood
Disrupting the Socs2-Mediated Negative Feedback to JAK-STAT Signaling Boosts Molecular Responses Induced By Interferon-α in a Mouse Model of Myeloproliferative Neoplasms
2022
·
Marc Usart
, Cédric B. Stoll
, et al.
·
Blood
Show more works
View as search
Works count:
17
Citation count:
450
H-index:
6
I10-index:
6
Year
Topic
Type